Feng DC, Li DX, Wu RC, Wang J, Xiao YH, Yoo KH, Ye X, Wei WR, Kong DP, Tuo ZT (2025) Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046. Mil Med Res 12(1):12

PubMed  PubMed Central  Google Scholar 

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders G, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouviere O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148–63. https://doi.org/10.1016/j.eururo.2024.03.027

Article  PubMed  Google Scholar 

Zhu X, Che X, Yang R, Bao B, Chu G (2025) Global, regional, and national burden of cancer in the elderly population, 1990–2021: analysis of data from the Global Burden of Disease Study 2021. Med Research. https://doi.org/10.1002/mdr2.70031

Article  Google Scholar 

Wang Z, Wang J, Li D, Wu R, Huang J, Ye L, Tuo Z, Yu Q, Shao F, Wusiman D, Cho WC, Koh SB, Xiong W, Feng D (2025) Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance. J Pharm Anal 15(9):101232

Article  PubMed  PubMed Central  Google Scholar 

Sonkin D, Thomas A, Teicher BA (2024) Cancer treatments: past, present, and future. Cancer Genet 286:18–24

Article  PubMed  Google Scholar 

Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701–711

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng D, Shi X, Wang J, Zhang L, Xiao Y, Li D, Wu R, Wei W, Miyamoto A, Yoo KH, Ye X, Zhang C, Han P (2024) Telemedicine-medical “snack community”-PHS ecosystem: insights into the double-edged sword role of telemedicine in clinical practice and medical education during the COVID-19 pandemic and beyond. Exploration Beijing 4(4):20230111

Article  PubMed  PubMed Central  Google Scholar 

Guo Z, Liu Y, Chen D, Sun Y, Li D, Meng Y, Zhou Q, Zeng F, Deng G, Chen X (2025) Targeting regulated cell death: apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity. J Transl Int Med 13(1):10–32

Article  PubMed  PubMed Central  Google Scholar 

Wu T, Ji M, Li T, Luo L (2025) The molecular and metabolic landscape of ferroptosis in respiratory diseases: pharmacological aspects. J Pharm Anal 15(1):101050

Article  PubMed  Google Scholar 

Zhang Y, Zou L, Li X, Guo L, Hu B, Ye H, Liu Y (2024) SLC40A1 in iron metabolism, ferroptosis, and disease: a review. WIREs Mech Dis 16(4):e1644

Article  CAS  PubMed  Google Scholar 

Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1–2):317–31. https://doi.org/10.1016/j.cell.2013.12.010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan M, Zhang J, Ji G, Fang X, Mo C (2025) Ferroptosis in pneumoconiosis: from molecular and cellular mechanisms to therapeutic strategies. Med Res 1(2):239–256

Google Scholar 

Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12(8):599–620

Article  CAS  PubMed  Google Scholar 

Lai W, Wang B, Huang R, Zhang C, Fu P, Ma L (2024) Ferroptosis in organ fibrosis: from mechanisms to therapeutic medicines. J Transl Intern Med 12(1):22–34

Article  Google Scholar 

Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Trumbach D, Mao G, Qu F, Bayir H, Fullekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, Conrad M (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13(1):91–98

Article  CAS  PubMed  Google Scholar 

Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T (2021) Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res 81(6):1583–1594

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lv D, Shi Y, Kou L, Zhang D, Guo Y, Zhao S (2025) Precision targeting of androgen receptor-ferroptosis crosstalk in prostate cancer: from mechanisms to therapeutic strategies. Pharmacol Res 219:107915

Article  CAS  PubMed  Google Scholar 

Liang J, Liao Y, Wang P, Yang K, Wang Y, Wang K, Zhong B, Zhou D, Cao Q, Li J, Zhao Y, Jiang N (2023) Ferroptosis landscape in prostate cancer from molecular and metabolic perspective. Cell Death Discov 9(1):128

Article  PubMed  PubMed Central  Google Scholar 

Pardella E, Comito G, Ippolito L, Pranzini E, Iozzo M, Gangarossa G, Virgilio F, Bua S, Nocentini A, Sandrini G, Lorito N, Bacci M, Nesi G, Spatafora P, Serni S, Supuran CT, Morandi A, Chiarugi P, Giannoni E (2025) Targeting carbonic anhydrase IX/XII prevents the anti-ferroptotic effect of stromal lactic acid in prostate carcinoma. Mol Oncol 19(9):2515–2536

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu B, Li X, Wang D, Yu Y, Lu D, Chen L, Lv F, Li Y, Cheng L, Song Y, Xing Y (2022) CEMIP promotes extracellular matrix-detached prostate cancer cell survival by inhibiting ferroptosis. Cancer Sci 113(6):2056–2070

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Xiang Y, Wang Q, Bai X, Meng D, Wu J, Sun K, Zhang L, Qiang R, Liu W, Zhang X, Qiang J, Liu X, Yang Y (2025) Regulation of iron metabolism in ferroptosis: from mechanism research to clinical translation. J Pharm Anal 15(10):101304

Article  PubMed  PubMed Central  Google Scholar 

Yu L, Huang K, Liao Y, Wang L, Sethi G, Ma Z (2024) Targeting novel regulated cell death: ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy. Cell Prolif 57(8):e13644

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang H, Zhang X, Jia Z, Wang H, Wu J, Wei X, Huang Y, Yan W, Lin Y (2025) Targeting ferroptosis in prostate cancer management: molecular mechanisms, multidisciplinary strategies and translational perspectives. J Transl Med 23(1):166

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Li J, Liu J, Gao Y, Li K, Zhao X, Liu Y, Wang D, Hu X, Wang Z (2025) Ferroptosis in osteoarthritis: towards novel therapeutic strategy. Cell Prolif 58(3):e13779

Article  CAS  PubMed  Google Scholar 

Ji J, Li H, Wang W, Yuan B, Shen T (2022) ARPC1A is regulated by STAT3 to inhibit ferroptosis and promote prostate cancer progression. Hum Cell 35(5):1591–1601

Article  CAS  PubMed  Google Scholar 

Baskar G (2025) GPX4 in triple-negative breast cancer: a key regulator of ferroptosis and therapeutic target. Cancer Genet 296–297:76–83. https://doi.org/10.1016/j.cancergen.2025.06.009

Article  CAS  PubMed  Google Scholar 

Cheng L, He Q, Liu B, Chen L, Lv F, Li X, Li Y, Liu C, Song Y, Xing Y (2023) SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4. Cell Death Dis 14(1):74. https://doi.org/10.1038/s41419-023-05614-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu P, Wang Y, Deng Z, Tan Z, Pei X (2022) MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression. Oncol Lett 23(2):67

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao X, Zhou T, Wang Y, Bao M, Ni C, Ding L, Sun S, Dong H, Li J, Liang C (2023) Trigred motif 36 regulates neuroendocrine differentiation of prostate cancer via HK2 ubiquitination and GPx4 deficiency. Cancer Sci 114(6):2445–2459

Article  CAS  PubMed